Board of Directors


Keith A. Katkin | Chairman of the Board of Directors

Mr. Katkin has served as Chairman of the Board of Directors of Novus Therapeutics, Inc. since the acquisition of Otic Pharma, Ltd. by Novus Therapeutics (formerly Tokai Pharmaceuticals, Inc.) in May 2017.  Prior to the acquisition, Mr. Katkin served as Chairman of the Board of Directors for Otic Pharma from 2015 to 2017.  Mr. Katkin previously served as President and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from 2007 to 2016. Mr. Katkin led the growth and ultimate sale of Avanir to Otsuka Pharmaceutical Co., Ltd. for $3.5 billion.  Mr. Katkin joined Avanir in 2005 as Senior Vice President of Sales and Marketing and a member of Avanir’s executive management team.  Prior to joining Avanir, Mr. Katkin served as Vice President, Commercial Development for Peninsula Pharmaceuticals, Inc., a privately-held biopharmaceutical company, playing a key role in the concurrent initial public offering and ultimate sale of the company to Johnson and Johnson.  Additionally, Mr. Katkin’s employment experience includes leadership roles at InterMune, Inc., Amgen, Inc. and Abbott Laboratories.  Mr. Katkin currently serves on the Board of Director of Avanir, Syndax Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., MC10, and the Brain Injury Association of America.  Mr. Katkin has an M.B.A. from the Anderson School of Business at UCLA and earned a B.S. in Business and Accounting from Indiana University. Mr. Katkin is also a certified public accountant.

Erez Chimovits M.Sc., MBA | Director

Mr. Chimovits has served as a member of the Board of Directors of Novus Therapeutics, Inc. since the acquisition of Otic Pharma, Ltd. by Novus Therapeutics (formerly Tokai Pharmaceuticals, Inc.) in May 2017.  Prior to the acquisition, Mr. Chimovits served as a member of the Board of Directors for Otic Pharma.  Mr. Chimovits is a Senior Managing Director at OrbiMed.  He has more than 14 years of operational experience, including 10 years of senior managerial experience in public companies.  Prior to joining OrbiMed, he was the Chief Executive Officer of NasVax (TASE: NSVX).  NasVax acquired Protea and struck key agreements with GlaxoSmithKline and Novartis.  Previously, Mr. Chimovits spent more than seven years with Compugen (Nasdaq: CGEN), as President, Compugen USA Inc. and Executive Vice President, Commercial Operations.  While at Compugen, he had P&L responsibility for more than 100 people and led multiple transactions including J&J, Novartis, Teva, Abbott, Medarex and others.  Mr. Chimovits earned his M.B.A., M.Sc. in Microbiology and his B.Sc. from Tel Aviv University.

Cheryl L. Cohen | Director

Ms. Cohen has served as a member of the Board of Directors of Novus Therapeutics, Inc. (formerly Tokai Pharmaceuticals, Inc.) since April 2015.  Ms. Cohen previously served as Chief Commercial Officer of Medivation, Inc. from 2011 to 2014.  Ms. Cohen currently serves as President of CLC Consulting, a pharmaceutical and biotechnology consulting firm specializing in new product start-up and commercialization, where she also served as President from 2008 to 2011.  Ms. Cohen also served as Vice President, Strategic Commercial Group, of Health Care Systems, Inc., a Johnson & Johnson company from 1998 to 2007, she worked at Janssen Biotech, Inc. (formerly Centocor Biotech, Inc.), a Johnson & Johnson company, in a variety of senior sales roles including Vice President, Rheumatology Franchise.  Ms. Cohen began her career at Solvay Pharmaceuticals in a variety of sales positions.  Ms. Cohen currently serves on the boards of directors of Protein Sciences Corp., a private company, and Vital Therapies, Inc., a publicly-traded company.  Ms. Cohen received her B.A. from Saint Joseph College.

 

Gregory J. Flesher | Director

Mr. Flesher has served as the President, Chief Executive Officer and a member of the Board of Directors of Novus Therapeutics, Inc. since the acquisition of Otic Pharma, Ltd. by Novus Therapeutics (formerly Tokai Pharmaceuticals, Inc.) in May 2017.  Prior to the acquisition, Mr. Flesher served as Chief Executive Officer and a member of the Board of Directors for Otic Pharma, Ltd. from 2015 to 2017.  Mr. Flesher has over 20 years of pharmaceutical industry experience and has been closely involved with several successful drug development programs that have resulted in multiple product approvals and commercial launches in the U.S. and Europe.  Prior to Otic Pharma, Mr. Flesher served as Senior Vice President of Corporate Development and Chief Business Officer, and other executive management roles at Avanir Pharmaceuticals, Inc. from 2006 to 2015.  Mr. Flesher previously served in various sales, marketing, and clinical development roles at InterMune, Inc., Amgen, Inc., and Eli Lilly and Company from 1995 to 2006.  Mr. Flesher earned his Bachelor of Science in Biology from Purdue University and studied Biochemistry and Molecular Biology at Indiana University School of Medicine.

Gary A. Lyons | Director

Mr. Lyons has served as a member of the Board of Directors of Novus Therapeutics, Inc. since May 2017.  Mr. Lyons has more than 35 years of industry experience.  Mr. Lyons is currently a member of the Board of Directors of Neurocrine Biosciences, Inc., a position he has held since 1993.  Mr. Lyons joined Neurocrine in 1993 and served as Chief Executive Officer until 2008.  Mr. Lyons also serves on the Board of Directors of Vical, Inc., Cytori Therapeutics, Inc., and is the Chairman of the Board of Directors for Rigel Pharmaceuticals, Inc. and Retrophin, Inc.  He previously served on the Board of Directors of PDL BioPharma, Inc. and Facet Biotech Corporation following Facet’s spin-off from PDL until Facet’s acquisition by Abbott Laboratories in 2010.  Mr. Lyons previously served on the Board of Directors of Poniard Pharmaceuticals, Inc., NeurogesX, Inc. and KaloBios Pharmaceuticals, Inc., each a biopharmaceutical company.  From 1983 to 1993, Mr. Lyons held a number of senior management positions at Genentech, including Vice President of Business Development and Vice President of Sales, and also served as a member of Genentech’s Executive Committee.  Mr. Lyons was responsible for international licensing, acquisitions and partnering for Genentech’s Corporate Venture Program and had operating responsibility for two subsidiaries, Genentech Canada, Inc. and Genentech Limited (Japan).  He holds a B.S. in Marine Biology from the University of New Hampshire and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management.

John S. McBride | Director

Mr. McBride has served as a member of the Board of Directors of Novus Therapeutics, Inc. (formerly Tokai Pharmaceuticals, Inc.) since May 2017.  Mr. McBride previously served as Chief Operating Officer, Chief Financial Officer, and interim Chief Financial Officer of Tokai Pharmaceuticals from 2014 until 2017.  Prior to Tokai, Mr. McBride founded and served as President of Alliance Life Science Advisors, Inc., a consulting firm focused on assisting life science companies with strategic planning, business development and financing projects from 2012 to 2014.  Prior to founding Alliance Life Science Advisors, Inc., Mr. McBride was an independent consultant from 2009 to 2012.  In addition, Mr. McBride previously served as Executive Vice President and Chief Operating Officer of Gloucester Pharmaceuticals, Inc., Global Head of Oncology Licensing at Pharmacia Corporation, Executive Vice President, Business Operations and Chief Financial Officer at CytoTherapeutics, Inc., Vice President, Business Development and Treasurer at Phytera, Inc., Vice President, Commercial Development at Sparta Pharmaceuticals, Inc., and Vice President, Business Development at U.S. Bioscience, Inc.  Mr. McBride holds a B.S. in Biochemistry and an M.S. in Chemical Engineering from the University of Wisconsin and an M.B.A. from the Wharton School, University of Pennsylvania.

Jodie P. Morrison | Director

Ms. Morrison has 20 years of broad experience in the pharmaceutical and biotech industries, including extensive operational and development leadership. From 2006 to 2017, Ms. Morrison held positions of increasing responsibility at Tokai Pharmaceuticals including serving her last 4 years as president and chief executive officer and a member of its board of directors. Prior to being appointed CEO, she served as Tokai’s chief operating officer and head of clinical affairs. Throughout her tenure at Tokai she oversaw the company’s development pipeline and led it’s operational management including the execution of the IPO and completion of the merger forming Novus Therapeutics. Prior to joining Tokai, Ms. Morrison was director of clinical operations and medical affairs at Dyax Corporation where she built and led the clinical development teams for the Kalbitor™ (hereditary angioedema) program. Before joining Dyax, she held clinical management positions at Curis, Inc. and Diacrin, Inc. Ms. Morrison has a B.A. in neuroscience from Mount Holyoke College, business training from the Greater Boston Executive Program at MIT Sloan School of Management and clinical research certification from Boston University School of Medicine.  In addition to her appointment at Novus, Ms. Morrison currently sits on the board of directors for Keryx Biopharmaceuticals (KERX).